Agios Presents Updated PYRUKYND (mitapivat) Long-term Extension Data Demonstrating Sustained Clinical Benefits in Adults with Pyruvate Kinase (PK) Deficiency at 64th ASH Annual Meeting and Exposition
12.12.2022 - – Data Suggest Long-term Treatment with PYRUKYND in Adults with PK Deficiency is Associated with Improvements in Hemoglobin, Iron Overload, Transfusion Burden and Patient-reported Outcomes, Regardless of Transfusion Status – – Additional Data ... Seite 1
Source: wallstreet-online.de